| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Multidrug-Resistant | 14 | 2024 | 226 | 3.560 |
Why?
|
| HIV Infections | 53 | 2024 | 5097 | 3.290 |
Why?
|
| Tuberculosis | 22 | 2024 | 543 | 2.920 |
Why?
|
| Antitubercular Agents | 17 | 2024 | 322 | 2.400 |
Why?
|
| Respiratory Tract Infections | 17 | 2024 | 266 | 2.060 |
Why?
|
| Influenza, Human | 22 | 2023 | 374 | 2.000 |
Why?
|
| Hospitalization | 20 | 2024 | 418 | 1.910 |
Why?
|
| South Africa | 87 | 2024 | 7596 | 1.880 |
Why?
|
| Humans | 107 | 2024 | 14537 | 1.840 |
Why?
|
| Adult | 68 | 2024 | 5913 | 1.780 |
Why?
|
| Middle Aged | 49 | 2024 | 3601 | 1.550 |
Why?
|
| Female | 72 | 2024 | 9103 | 1.540 |
Why?
|
| Male | 64 | 2024 | 6754 | 1.530 |
Why?
|
| Mycobacterium tuberculosis | 10 | 2024 | 329 | 1.300 |
Why?
|
| Rifampin | 11 | 2024 | 197 | 1.230 |
Why?
|
| Respiratory Syncytial Virus Infections | 8 | 2024 | 200 | 1.190 |
Why?
|
| Aged | 28 | 2024 | 1740 | 1.140 |
Why?
|
| Linezolid | 4 | 2024 | 22 | 1.110 |
Why?
|
| Hospital Mortality | 2 | 2019 | 95 | 1.090 |
Why?
|
| Young Adult | 38 | 2024 | 2498 | 1.050 |
Why?
|
| Tuberculosis, Pulmonary | 9 | 2024 | 324 | 1.050 |
Why?
|
| Isoniazid | 4 | 2024 | 110 | 1.020 |
Why?
|
| Respiratory Syncytial Virus, Human | 7 | 2024 | 155 | 1.000 |
Why?
|
| Drug Interactions | 2 | 2024 | 31 | 0.970 |
Why?
|
| Clofazimine | 3 | 2024 | 8 | 0.940 |
Why?
|
| Levofloxacin | 3 | 2024 | 21 | 0.930 |
Why?
|
| Child | 37 | 2024 | 2242 | 0.910 |
Why?
|
| Child, Preschool | 35 | 2024 | 1748 | 0.910 |
Why?
|
| Prevalence | 23 | 2024 | 1192 | 0.890 |
Why?
|
| Diarylquinolines | 8 | 2024 | 39 | 0.870 |
Why?
|
| Guideline Adherence | 1 | 2024 | 43 | 0.870 |
Why?
|
| Cycloserine | 1 | 2024 | 2 | 0.860 |
Why?
|
| Nitroimidazoles | 6 | 2024 | 24 | 0.860 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 127 | 0.840 |
Why?
|
| Adolescent | 36 | 2024 | 2985 | 0.820 |
Why?
|
| Hypertension | 2 | 2024 | 419 | 0.750 |
Why?
|
| Anti-HIV Agents | 7 | 2024 | 1324 | 0.750 |
Why?
|
| Prospective Studies | 21 | 2024 | 1160 | 0.700 |
Why?
|
| Cost of Illness | 6 | 2020 | 167 | 0.690 |
Why?
|
| Infant | 28 | 2024 | 2244 | 0.680 |
Why?
|
| Risk Factors | 17 | 2024 | 1475 | 0.670 |
Why?
|
| Pyrazinamide | 4 | 2024 | 14 | 0.660 |
Why?
|
| Cross-Sectional Studies | 13 | 2024 | 1422 | 0.650 |
Why?
|
| Drug Therapy, Combination | 10 | 2024 | 279 | 0.650 |
Why?
|
| Coinfection | 10 | 2017 | 276 | 0.640 |
Why?
|
| Piperazines | 5 | 2024 | 82 | 0.640 |
Why?
|
| Oxazines | 5 | 2024 | 81 | 0.640 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 5 | 2024 | 85 | 0.630 |
Why?
|
| Morbidity | 1 | 2019 | 37 | 0.630 |
Why?
|
| Pyridones | 5 | 2024 | 100 | 0.630 |
Why?
|
| Patient Readmission | 1 | 2019 | 6 | 0.620 |
Why?
|
| Pharmaceutical Preparations | 1 | 2019 | 44 | 0.610 |
Why?
|
| HIV-1 | 6 | 2024 | 1260 | 0.610 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 239 | 0.590 |
Why?
|
| Strikes, Employee | 1 | 2018 | 1 | 0.590 |
Why?
|
| Tenofovir | 2 | 2017 | 171 | 0.590 |
Why?
|
| Treatment Outcome | 15 | 2024 | 889 | 0.580 |
Why?
|
| Mortality | 1 | 2019 | 104 | 0.580 |
Why?
|
| Physicians | 1 | 2018 | 31 | 0.580 |
Why?
|
| Benzoxazines | 2 | 2021 | 123 | 0.560 |
Why?
|
| Contact Tracing | 5 | 2020 | 48 | 0.550 |
Why?
|
| Ataxia | 1 | 2017 | 4 | 0.540 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 253 | 0.530 |
Why?
|
| Brain Diseases | 1 | 2017 | 24 | 0.530 |
Why?
|
| Health Services Accessibility | 3 | 2018 | 280 | 0.530 |
Why?
|
| Retrospective Studies | 7 | 2023 | 799 | 0.510 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 15 | 0.500 |
Why?
|
| Health Care Costs | 3 | 2023 | 115 | 0.500 |
Why?
|
| Sentinel Surveillance | 7 | 2024 | 115 | 0.470 |
Why?
|
| Fatty Liver | 1 | 2015 | 8 | 0.450 |
Why?
|
| Patient Discharge | 4 | 2024 | 27 | 0.450 |
Why?
|
| Liver | 1 | 2015 | 74 | 0.440 |
Why?
|
| Orthomyxoviridae | 4 | 2018 | 33 | 0.430 |
Why?
|
| Virus Diseases | 3 | 2023 | 55 | 0.420 |
Why?
|
| Anti-Retroviral Agents | 6 | 2024 | 551 | 0.420 |
Why?
|
| Latent Tuberculosis | 3 | 2020 | 45 | 0.410 |
Why?
|
| Acute Disease | 6 | 2018 | 105 | 0.400 |
Why?
|
| Sputum | 6 | 2019 | 135 | 0.390 |
Why?
|
| Rhinovirus | 3 | 2019 | 23 | 0.380 |
Why?
|
| Inpatients | 4 | 2019 | 30 | 0.370 |
Why?
|
| Viral Load | 9 | 2024 | 819 | 0.360 |
Why?
|
| HIV Integrase Inhibitors | 2 | 2021 | 33 | 0.350 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2018 | 256 | 0.350 |
Why?
|
| Viruses | 4 | 2022 | 47 | 0.350 |
Why?
|
| Lamivudine | 2 | 2024 | 89 | 0.340 |
Why?
|
| Communicable Diseases | 2 | 2023 | 62 | 0.330 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2018 | 656 | 0.320 |
Why?
|
| Whooping Cough | 2 | 2021 | 36 | 0.320 |
Why?
|
| Primary Health Care | 2 | 2024 | 240 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 139 | 0.310 |
Why?
|
| Tuberculin Test | 5 | 2020 | 49 | 0.300 |
Why?
|
| Incidence | 10 | 2024 | 685 | 0.290 |
Why?
|
| Influenza Vaccines | 3 | 2021 | 144 | 0.290 |
Why?
|
| Lung | 2 | 2021 | 70 | 0.280 |
Why?
|
| Family Characteristics | 6 | 2020 | 135 | 0.280 |
Why?
|
| Pneumonia, Pneumococcal | 4 | 2024 | 100 | 0.270 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 2 | 2018 | 20 | 0.260 |
Why?
|
| Picornaviridae Infections | 2 | 2019 | 18 | 0.260 |
Why?
|
| Mass Screening | 4 | 2018 | 245 | 0.260 |
Why?
|
| Cohort Studies | 5 | 2021 | 967 | 0.250 |
Why?
|
| Hospitals | 3 | 2023 | 103 | 0.250 |
Why?
|
| Infant, Newborn | 9 | 2024 | 1479 | 0.240 |
Why?
|
| Community-Acquired Infections | 2 | 2024 | 102 | 0.240 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2015 | 10 | 0.240 |
Why?
|
| Surveys and Questionnaires | 5 | 2018 | 563 | 0.230 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2018 | 195 | 0.230 |
Why?
|
| Aged, 80 and over | 8 | 2023 | 468 | 0.230 |
Why?
|
| Fluoroquinolones | 4 | 2022 | 20 | 0.230 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 156 | 0.230 |
Why?
|
| Smoking Cessation | 1 | 2024 | 9 | 0.220 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 64 | 0.220 |
Why?
|
| Home Care Services | 1 | 2024 | 15 | 0.210 |
Why?
|
| Vaccination | 4 | 2020 | 365 | 0.210 |
Why?
|
| HIV Seropositivity | 3 | 2022 | 265 | 0.210 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 171 | 0.200 |
Why?
|
| Population Surveillance | 4 | 2018 | 325 | 0.200 |
Why?
|
| Hypoglycemia | 1 | 2023 | 4 | 0.200 |
Why?
|
| Nicotine | 1 | 2023 | 12 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2023 | 22 | 0.200 |
Why?
|
| Bordetella pertussis | 2 | 2021 | 29 | 0.190 |
Why?
|
| Logistic Models | 4 | 2017 | 254 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 262 | 0.190 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 21 | 0.190 |
Why?
|
| Blood Pressure | 1 | 2024 | 317 | 0.190 |
Why?
|
| Anemia | 1 | 2022 | 41 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 34 | 0.190 |
Why?
|
| Physical Abuse | 1 | 2022 | 8 | 0.180 |
Why?
|
| Sex Offenses | 1 | 2022 | 29 | 0.180 |
Why?
|
| Pneumococcal Vaccines | 1 | 2024 | 278 | 0.180 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 51 | 0.180 |
Why?
|
| Mycoses | 1 | 2021 | 8 | 0.180 |
Why?
|
| Endemic Diseases | 1 | 2021 | 15 | 0.180 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 18 | 0.180 |
Why?
|
| Alkynes | 2 | 2021 | 117 | 0.180 |
Why?
|
| Cyclopropanes | 2 | 2021 | 123 | 0.180 |
Why?
|
| Epidemiological Monitoring | 2 | 2019 | 45 | 0.170 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 40 | 0.170 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 2 | 0.170 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2021 | 4 | 0.170 |
Why?
|
| International Cooperation | 1 | 2021 | 50 | 0.170 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 44 | 0.170 |
Why?
|
| Influenza A virus | 2 | 2018 | 28 | 0.170 |
Why?
|
| Enterovirus | 2 | 2017 | 9 | 0.170 |
Why?
|
| Cell Phone | 1 | 2020 | 34 | 0.170 |
Why?
|
| Enterovirus Infections | 2 | 2017 | 10 | 0.170 |
Why?
|
| Enterovirus D, Human | 2 | 2017 | 10 | 0.170 |
Why?
|
| Sex Workers | 1 | 2022 | 116 | 0.160 |
Why?
|
| Global Health | 1 | 2021 | 193 | 0.160 |
Why?
|
| Urine | 2 | 2010 | 6 | 0.160 |
Why?
|
| Prognosis | 2 | 2019 | 199 | 0.160 |
Why?
|
| Lipopolysaccharides | 2 | 2010 | 37 | 0.160 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 5 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2019 | 90 | 0.160 |
Why?
|
| Tobacco, Smokeless | 1 | 2019 | 7 | 0.150 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 109 | 0.150 |
Why?
|
| Tobacco Use | 1 | 2019 | 12 | 0.150 |
Why?
|
| Absenteeism | 1 | 2019 | 10 | 0.150 |
Why?
|
| Life Expectancy | 1 | 2019 | 31 | 0.150 |
Why?
|
| Molecular Typing | 1 | 2019 | 12 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 43 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2016 | 149 | 0.150 |
Why?
|
| Oxazoles | 1 | 2019 | 4 | 0.150 |
Why?
|
| Virus Shedding | 1 | 2018 | 24 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 33 | 0.150 |
Why?
|
| Age Factors | 1 | 2019 | 370 | 0.150 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 15 | 0.140 |
Why?
|
| Health Education | 1 | 2018 | 35 | 0.140 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2018 | 13 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 4 | 2020 | 253 | 0.140 |
Why?
|
| Resins, Synthetic | 1 | 2018 | 3 | 0.140 |
Why?
|
| Health Facilities | 1 | 2018 | 40 | 0.140 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2018 | 4 | 0.140 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2018 | 4 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2018 | 54 | 0.140 |
Why?
|
| Nasopharynx | 5 | 2018 | 151 | 0.140 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 111 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2018 | 56 | 0.140 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2017 | 5 | 0.140 |
Why?
|
| Air Pollution, Indoor | 1 | 2017 | 13 | 0.140 |
Why?
|
| Directive Counseling | 1 | 2017 | 15 | 0.130 |
Why?
|
| Phylogeny | 4 | 2021 | 231 | 0.130 |
Why?
|
| Comorbidity | 4 | 2019 | 188 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 125 | 0.130 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 132 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2018 | 175 | 0.130 |
Why?
|
| Asymptomatic Infections | 1 | 2017 | 34 | 0.130 |
Why?
|
| Blood Urea Nitrogen | 1 | 2017 | 6 | 0.130 |
Why?
|
| Bacteriological Techniques | 2 | 2015 | 54 | 0.130 |
Why?
|
| ROC Curve | 1 | 2017 | 51 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 106 | 0.130 |
Why?
|
| Genotype | 4 | 2021 | 442 | 0.130 |
Why?
|
| Bacteremia | 2 | 2014 | 79 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2017 | 120 | 0.130 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 71 | 0.130 |
Why?
|
| Seasons | 4 | 2019 | 154 | 0.120 |
Why?
|
| Uganda | 3 | 2022 | 197 | 0.120 |
Why?
|
| Legionnaires' Disease | 1 | 2016 | 3 | 0.120 |
Why?
|
| Respirovirus | 1 | 2015 | 4 | 0.120 |
Why?
|
| Length of Stay | 2 | 2012 | 43 | 0.120 |
Why?
|
| RNA, Viral | 3 | 2024 | 303 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2015 | 39 | 0.120 |
Why?
|
| Pneumovirus Infections | 1 | 2015 | 7 | 0.120 |
Why?
|
| Lopinavir | 1 | 2016 | 137 | 0.120 |
Why?
|
| Inservice Training | 1 | 2015 | 7 | 0.120 |
Why?
|
| Sensitivity and Specificity | 5 | 2019 | 385 | 0.120 |
Why?
|
| Allied Health Personnel | 1 | 2015 | 6 | 0.120 |
Why?
|
| Ritonavir | 1 | 2016 | 137 | 0.120 |
Why?
|
| Metapneumovirus | 1 | 2015 | 30 | 0.110 |
Why?
|
| Granuloma | 1 | 2015 | 3 | 0.110 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 11 | 0.110 |
Why?
|
| Nevirapine | 1 | 2016 | 146 | 0.110 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 23 | 0.110 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 12 | 0.110 |
Why?
|
| Politics | 1 | 2015 | 24 | 0.110 |
Why?
|
| Bronchopneumonia | 1 | 2015 | 11 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 28 | 0.110 |
Why?
|
| Rural Health Services | 1 | 2015 | 48 | 0.110 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 278 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 125 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 17 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2015 | 104 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 42 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2024 | 179 | 0.100 |
Why?
|
| Time Factors | 4 | 2016 | 507 | 0.100 |
Why?
|
| Public Health Surveillance | 3 | 2019 | 52 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 370 | 0.090 |
Why?
|
| Europe | 2 | 2021 | 56 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2019 | 133 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2024 | 42 | 0.080 |
Why?
|
| Ethambutol | 2 | 2024 | 9 | 0.080 |
Why?
|
| Pandemics | 2 | 2023 | 296 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 112 | 0.080 |
Why?
|
| Autopsy | 2 | 2023 | 140 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 188 | 0.070 |
Why?
|
| Pregnancy | 3 | 2020 | 1862 | 0.070 |
Why?
|
| Self Report | 2 | 2019 | 114 | 0.070 |
Why?
|
| Animals | 2 | 2021 | 1081 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 293 | 0.070 |
Why?
|
| History, 21st Century | 2 | 2018 | 42 | 0.070 |
Why?
|
| Tanzania | 2 | 2019 | 88 | 0.070 |
Why?
|
| Drug Monitoring | 2 | 2019 | 55 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 181 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 77 | 0.060 |
Why?
|
| Cotinine | 1 | 2024 | 7 | 0.060 |
Why?
|
| Equivalence Trials as Topic | 1 | 2024 | 7 | 0.050 |
Why?
|
| House Calls | 1 | 2024 | 9 | 0.050 |
Why?
|
| Bacterial Load | 2 | 2014 | 32 | 0.050 |
Why?
|
| Counseling | 1 | 2024 | 143 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2024 | 118 | 0.050 |
Why?
|
| Health Care Sector | 1 | 2023 | 8 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2023 | 28 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 42 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2024 | 480 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2022 | 6 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2022 | 19 | 0.050 |
Why?
|
| Aminoglycosides | 1 | 2022 | 5 | 0.050 |
Why?
|
| Ferritins | 1 | 2022 | 23 | 0.050 |
Why?
|
| Iron | 1 | 2022 | 32 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 101 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2022 | 23 | 0.050 |
Why?
|
| Smoking | 1 | 2023 | 100 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 81 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 109 | 0.050 |
Why?
|
| Cholesterol | 1 | 2021 | 38 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2022 | 225 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 127 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 106 | 0.040 |
Why?
|
| Pertussis Vaccine | 1 | 2021 | 16 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 62 | 0.040 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2021 | 4 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 1 | 2021 | 92 | 0.040 |
Why?
|
| Biomarkers | 1 | 2022 | 327 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 24 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 2 | 2014 | 336 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2021 | 8 | 0.040 |
Why?
|
| Thailand | 1 | 2021 | 26 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 198 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2021 | 120 | 0.040 |
Why?
|
| World Health Organization | 1 | 2021 | 137 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 435 | 0.040 |
Why?
|
| Body Weight | 1 | 2021 | 111 | 0.040 |
Why?
|
| Fever | 1 | 2019 | 26 | 0.040 |
Why?
|
| Child, Hospitalized | 1 | 2019 | 26 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 16 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2019 | 21 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 30 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 87 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 80 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 38 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 63 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 74 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2018 | 18 | 0.040 |
Why?
|
| Aftercare | 1 | 2018 | 10 | 0.040 |
Why?
|
| Smokers | 1 | 2018 | 3 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 23 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 80 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 272 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 2018 | 49 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 135 | 0.030 |
Why?
|
| Kerosene | 1 | 2017 | 4 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 16 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2017 | 8 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2018 | 203 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2017 | 45 | 0.030 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2016 | 29 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 38 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 175 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 150 | 0.030 |
Why?
|
| HIV | 1 | 2018 | 380 | 0.030 |
Why?
|
| Legionella | 1 | 2016 | 3 | 0.030 |
Why?
|
| Legionellosis | 1 | 2016 | 3 | 0.030 |
Why?
|
| Legionella pneumophila | 1 | 2016 | 3 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 231 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 321 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2015 | 3 | 0.030 |
Why?
|
| Family Health | 1 | 2015 | 16 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 31 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 27 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 54 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 14 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2015 | 14 | 0.030 |
Why?
|
| Models, Biological | 1 | 2015 | 77 | 0.030 |
Why?
|
| Automation, Laboratory | 1 | 2015 | 13 | 0.030 |
Why?
|
| Schools | 1 | 2015 | 73 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 217 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2014 | 47 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2014 | 42 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 263 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 260 | 0.030 |
Why?
|
| Suburban Health Services | 1 | 2012 | 2 | 0.020 |
Why?
|
| Urban Health Services | 1 | 2012 | 10 | 0.020 |
Why?
|
| Drug Costs | 1 | 2012 | 18 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2012 | 17 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 19 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 7 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 83 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 91 | 0.020 |
Why?
|
| Public Sector | 1 | 2012 | 82 | 0.020 |
Why?
|
| Therapeutic Equipoise | 1 | 2010 | 4 | 0.020 |
Why?
|
| Urban Population | 1 | 2012 | 257 | 0.020 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2010 | 33 | 0.020 |
Why?
|
| Microscopy | 1 | 2009 | 21 | 0.020 |
Why?
|
| Blood | 1 | 2009 | 51 | 0.020 |
Why?
|